抗体的发展过程及临床应用

曲艺; 李志勇; 缪朝玉

doi:10.3969/j.issn.1006-0111.2017.04.004

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

抗体的发展过程及临床应用

曲艺, 李志勇, 缪朝玉

文章导航 > 药学实践与服务 > 2017 > 35(4): 301-303,333

曲艺, 李志勇, 缪朝玉. 抗体的发展过程及临床应用[J]. 药学实践与服务, 2017, 35(4): 301-303,333. doi: 10.3969/j.issn.1006-0111.2017.04.004

引用本文:

曲艺, 李志勇, 缪朝玉. 抗体的发展过程及临床应用[J]. 药学实践与服务, 2017, 35(4): 301-303,333. doi: 10.3969/j.issn.1006-0111.2017.04.004

QU Yi, LI Zhiyong, MIAO Chaoyu. Development process and clinic applications of antibody[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 301-303,333. doi: 10.3969/j.issn.1006-0111.2017.04.004

Citation:

QU Yi, LI Zhiyong, MIAO Chaoyu. Development process and clinic applications of antibody[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 301-303,333. doi: 10.3969/j.issn.1006-0111.2017.04.004

抗体的发展过程及临床应用

doi: 10.3969/j.issn.1006-0111.2017.04.004

第二军医大学药学院药理学教研室, 上海 200433

基金项目: 国家自然科学基金资助项目（81130061，81202572，81373414）；上海市科学技术委员会科研计划项目（16JC1405100）

Development process and clinic applications of antibody

Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

摘要: 单克隆抗体已经成为生物技术和制药领域的重要组成部分，目前多用基因工程制备嵌合抗体、人源化抗体、全人抗体。随着制备抗体技术的不断进步，其应用也越来越广泛，特别是抗体药物正迅速发展。近几年出现了许多具有里程碑意义的抗体药物，如程序性死亡受体1（PD-1）抗体、白介素17A（IL-17A）抗体、白介素5（IL-5）抗体、前蛋白转化酶枯草杆菌转化酶/可馨型9（PCSK9）抗体等，用于多种疾病的治疗，解决了不少临床难题。在现代医学中，单克隆抗体已经成为有效的治疗手段和诊断工具。本文结合中外文献主要介绍抗体的发展过程、抗体在临床方面的应用及近几年来FDA批准的具有重大意义的抗体药物。
- 单克隆抗体 /
- 基因工程 /
- 临床应用
Abstract: Monoclonal antibodies have become an important part of biotechnology and pharmaceutical industry. Currently chimeric antibody, humanized antibody and fully human antibody are generally prepared by genetic engineering. With constant improvement in the antibody preparation technology, the antibody applications are rapidly increasing, especially in the development of antibody medications. In recent years, there have been many significant antibody drugs (such as PD-1 antibody, IL-17 antibody, IL-5 antibody, PCSK9 antibody) for the treatment of various diseases and solved a number of clinical problems. In modern medicine, monoclonal antibodies have become effective diagnostic and therapeutic tools. This article is a brief review of the recent antibody development process, clinic applications and significant antibody drugs approved by FDA.
- monoclonal antibody /
- genetic engineering /
- clinic application

[1]	Dixit R, Herz J, Dalton R, et al. Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens[J]. Vaccine, 2016, 34(9):1152-1161.
[2]	Gaughan CL. The present state of the art in expression, production and characterization of monoclonal antibodies[J]. Mol Divers, 2016, 20(1):255-270.
[3]	Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms[J]. Curr Opin Immunol, 2008, 20(4):450-459.
[4]	Bruggemann M, Osborn MJ, Ma B, et al. Human antibody production in transgenic animals[J]. Arch Immunol Ther Exp (Warsz), 2015, 63(2):101-108.
[5]	de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches[J]. Curr Opin Immunol, 2016, 40:14-23.
[6]	Yamada T. Therapeutic monoclonal antibodies[J]. Keio J Med, 2011, 60(2):37-46.
[7]	Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J]. Cancer Treat Rev, 2016, 45:7-18.
[8]	Fala L. Cosentyx (Secukinumab): First IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis[J]. Am Health Drug Benefits, 2016, 9(Spec Feature):60-63.
[9]	Maselli DJ, Velez MI, Rogers L. Reslizumab in the management of poorly controlled asthma: the data so far[J]. J Asthma Allergy, 2016, 9:155-162.
[10]	Lim BN, Tye GJ, Choong YS, et al. Principles and application of antibody libraries for infectious diseases[J]. Biotechnol Lett, 2014, 36(12):2381-2392.
[11]	Uchtenhagen H, Schiffner T, Bowles E, et al. Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein[J]. J Immunol, 2014, 192(12):5802-5812.
[12]	Pleass RJ, Holder AA. Opinion: antibody-based therapies for malaria[J]. Nat Rev Microbiol, 2005, 3(11):893-899.
[13]	Balu S, Reljic R, Lewis MJ, et al. A novel human IgA monoclonal antibody protects against tuberculosis[J]. J Immunol, 2011, 186(5):3113-3119.
[14]	Chapman MJ, Stock JK, Ginsberg HN. PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era[J]. Curr Opin Lipidol, 2015, 26(6):511-520.
[15]	Freskgard PO, Urich E. Antibody therapies in CNS diseases[J]. Neuropharmacology, 2016,DOI: 10.1016/j.neuropharm.2016.03.014.
[16]	Cohan S. Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis[J]. Biologics, 2016, 10:119-138.

[1]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[2]	张广雨, 杜晶, 刘梦珍, 朱丹妮, 闫慧, 刘冲. 新斯的明与山莨菪碱联合应用对肺型氧中毒的保护作用及其机制的研究 . 药学实践与服务, 2024, 42(10): 433-438, 444. doi: 10.12206/j.issn.2097-2024.202310049
[3]	王雪莲, 郑斯莉, 李志勇, 罗亨宇, 缪朝玉. 全身过表达人METRNL基因小鼠模型的构建与验证 . 药学实践与服务, 2024, 42(5): 198-202, 222. doi: 10.12206/j.issn.2097-2024.202311014
[4]	刘依秦, 王超群, 邱娇娜. 胆宁片预处理在糖尿病患者结肠镜检查前的应用效果分析 . 药学实践与服务, 2024, 42(9): 407-410. doi: 10.12206/j.issn.2097-2024.202407037
[5]	陈春娟, 郑志新, 李骊. 平喘方联合孟鲁司特钠治疗儿童支气管哮喘患者的临床疗效观察 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405035
[6]	王晓飞, 张颖, 顾佳钰, 胡馨儿, 张海, 曹岩. 表面等离子共振传感器的识别元件在医药领域中的研究应用进展 . 药学实践与服务, 2024, 42(): 1-9. doi: 10.12206/j.issn.2097-2024.202309014
[7]	丁千雪, 尚圣兰, 余梦辰, 余爱荣. 机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
[8]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[9]	崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺. 临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
[10]	黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉. 耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
[11]	杨凤艳, 张月, 陈恩贤, 缪雪蓉, 魏凯. 瑞马唑仑临床应用研究进展 . 药学实践与服务, 2024, 42(9): 365-374. doi: 10.12206/j.issn.2097-2024.202405026

点击查看大图

计量

文章访问数: 4926
HTML全文浏览量: 598
PDF下载量: 1205
被引次数: 0

抗体的发展过程及临床应用

doi: 10.3969/j.issn.1006-0111.2017.04.004

第二军医大学药学院药理学教研室, 上海 200433

基金项目: 国家自然科学基金资助项目（81130061，81202572，81373414）；上海市科学技术委员会科研计划项目（16JC1405100）

收稿日期: 2016-10-27
修回日期: 2017-02-20

关键词:

单克隆抗体 /

基因工程 /

临床应用

摘要: 单克隆抗体已经成为生物技术和制药领域的重要组成部分，目前多用基因工程制备嵌合抗体、人源化抗体、全人抗体。随着制备抗体技术的不断进步，其应用也越来越广泛，特别是抗体药物正迅速发展。近几年出现了许多具有里程碑意义的抗体药物，如程序性死亡受体1（PD-1）抗体、白介素17A（IL-17A）抗体、白介素5（IL-5）抗体、前蛋白转化酶枯草杆菌转化酶/可馨型9（PCSK9）抗体等，用于多种疾病的治疗，解决了不少临床难题。在现代医学中，单克隆抗体已经成为有效的治疗手段和诊断工具。本文结合中外文献主要介绍抗体的发展过程、抗体在临床方面的应用及近几年来FDA批准的具有重大意义的抗体药物。